Los Angeles, CA, United States
Los Angeles, CA, United States

Time filter

Source Type

News Article | April 25, 2017
Site: marketersmedia.com

Two of the top-rated Cardiologists in Las Vegas, Sean Ameli, M.D. and Berge Dadourian, M.D., have expanded their Concierge Cardiology practice to include Primary Care services. Ameli-Dadourian Heart Center is the first concierge medical practice in Las Vegas to offer Cardiology Medicine and Primary Care.​Las Vegas, United States - April 25, 2017 /PressCable/ — Ameli | Dadourian Heart Center is the first concierge medical practice in Las Vegas to offer Cardiology Medicine and Primary Care. LAS VEGAS, NV, March 1, 2017 – Two of the top-rated Cardiologists in Las Vegas, Sean Ameli, M.D. and Berge Dadourian, M.D., have expanded their Concierge Cardiology practice to include Primary Care services. Dr. Ameli and Dr. Dadourian, are Board Certified in both Cardiovascular and Internal Medicine. They served as Chief Residents and Clinical Instructors at UCLA-Cedars Sinai Medical Centers. In August of 2015, Ameli | Dadourian Heart Center established the first Concierge Cardiology Practice in Las Vegas. These health care leaders are now the first and only Cardiology and Internal Medicine Practice to offer patients a continuum of care by adding Concierge Primary Care to their Cardiology practice. The Ameli | Dadourian Heart Center is uniquely positioned to offer this personal, integrated health care model to Las Vegas residents. “Our concierge Cardiology practice allows us to spend more time with the patient in a non-rushed setting which typically leads to better outcomes,” said Sean Ameli, M.D., a partner in the Ameli | Dadourian Heart Center. “Now, by expanding this personal approach to also focus on primary care, we are providing that same attention required to diagnose and treat acute and chronic illnesses and address disease prevention, health maintenance, and patient education.” According to Berge Dadourian, M.D., “We take as much time as needed to learn of each patient’s needs and concerns.” Patients at the Ameli | Dadourian Heart Center can now select Cardiology membership or the expanded combined Primary Care with Cardiology Care option. “The addition of Primary Care services now gives us the opportunity to coordinate a patient’s complete care and eliminate the need for multiple doctors and appointments. We can be more efficient and help reduce redundant appointments and testing,” said Dr. Dadourian. Ameli | Dadourian Heart Center provides highly rated, personalized cardiology and primary care services to its members. A variety of diagnostic tests offered in the office include Ultrasounds, EKG, Lab draws, Treadmill, Pacemaker Checks, Pulmonary Function, Nuclear Medicine, and Holter Monitoring. Dr. Ameli and Dr. Dadourian have a combined 50 years of experience and have trained at some of the most prestigious programs and universities in the United States. The Ameli | Dadourian Heart Center accepts Medicare and most insurance plans. About Ameli | Dadourian Heart Center The Ameli | Dadourian Heart Center is a concierge cardiology and primary care practice located in Tivoli Village in Summerlin in Las Vegas, NV. Their patients have access to same day or next day appointments, phones are answered by the friendly and knowledgeable team, assistance in scheduling other medical services, same day prescription refill, and ongoing educational and preventive programs. Learn more about Ameli | Dadourian Heart Center at www.ameliheartcenter.com or call 702.906.1100. Contact Info:Name: Amy GodsoeEmail: agodsoe@ameliheartcenter.comOrganization: Ameli | Dadourian Heart CenterAddress: 400 South Rampart Boulevard Suite 240, Las Vegas, Nevada 89145, United StatesPhone: +1-702-906-1100For more information, please visit http://www.ameliheartcenter.comSource: PressCableRelease ID: 189811

News Article | May 4, 2017
Site: globenewswire.com

The video commerce company participates in the annual star-studded event MINNEAPOLIS, May 04, 2017 (GLOBE NEWSWIRE) -- Evine Live Inc. (“Evine”) (NASDAQ:EVLV), a multiplatform video commerce company (evine.com), today announced that it will support the 24th annual Race to Erase MS Gala on May 5, held at The Beverly Hilton in Los Angeles. A platinum sponsor of the star-studded gala, Evine is making a financial donation as well as donating several auction items to help raise funds in the fight against multiple sclerosis (MS), a disease that impacts over 2 million people worldwide. Following the gala event, Nancy Davis will appear live on Evine on May 19 - 21 with her signature “Peace & Love” branded product, including a co-branded timepiece created in partnership with Invicta, Evine’s best-selling watch brand. “It is an honor for Evine to partner with Nancy Davis and the Race to Erase MS to help find a cure for multiple sclerosis,” said Bob Rosenblatt, Chief Executive Officer of Evine. “MS is a disease that impacts some of our closest vendors, investors and customers, and we are humbled to support such a worthy cause. I look forward to having the opportunity to demonstrate Evine’s ‘Be Good to Others’ mantra as we partner with Nancy to help support research toward eradicating this debilitating disease.” The Race to Erase MS was founded by Davis in 1993 after being diagnosed with the disease. Since 1994, the foundation has raise more than $46 million in contributions. Funding research is the core focus of the foundation, with all funds raised supporting the Center Without Walls program, a nationwide collaboration of physicians and scientists all working to find a cure. “When I was first diagnosed, there were no drugs on the market to help stop the progression of MS. Today, there are 15 FDA-approved drugs to treat the symptoms of MS, and the FDA recently approved Ocrevus, which helps people with relapsing remitting MS in addition to people with primary progressive MS,” said Nancy David, founder of Race to Erase MS and owner of Peace & Love Jewelry. “That progress gives me hope and makes me grateful for all the people and organizations who have supported the Race to Erase MS. Evine has been an amazing partner over the past two years. The company’s generosity and willingness to raise awareness and money for MS research keeps our hope for finding a cure alive.” Happening on Friday, May 5, the 24th annual Race to Erase MS Gala is a star-studded event frequented by some of the biggest names in Hollywood. This year’s event will honor Jamie-Lynn Sigler, most notably known for her role as Meadow Soprano on HBO’s “The Sopranos,” with the 2017 Medal of Hope Award. Evine will send its own star-power, with host Heather Hall interviewing attendees on the red carpet along with Dr. Terry and Heather Dubrow as guests of honor. In addition to the financial donation, Evine will also offer several auction items, including an “Evine Experience.” As part of the experience, the auction’s winner would receive a two-night travel package to Evine studios, including airfare and hotel for two. While at the studios, the winner would be given a backstage tour, the opportunity to pitch their product and a chance to sell a product live on Evine’s television network. Invicta, Evine’s best-selling watch brand, has also created a timepiece especially for Davis’ foundation. Based on the popular Invicta Peace & Love watch released in early 2015, this year’s Invicta Peace & Love Lupah will be offered in both men’s and women’s styles and include six additional easy-to-change colorful straps. Each timepiece proudly displays Nancy Davis’s signature Peace & Love logo on its dial and comes packaged in a specially-designed gift box. Returning to Evine May 19 at 8pm ET, May 20 at 1am, 3pm and 8pm ET, and May 21 throughout the day, Davis will present the co-branded watch and new pieces from her Peace & Love gemstone jewelry collection, including a white topaz and zircon adjustable bracelet, offered in 14 different styles. For more information on the Race to Erase MS, visit www.erasems.org. To bid on the “Evine Experience,” visit http://bit.ly/2oMxhPK. For more information on Evine and to shop Davis’ full collection, go to www.evine.com/peaceandlove. About Evine Evine Live Inc. (NASDAQ:EVLV) operates Evine, a multiplatform video commerce company that offers a compelling mix of proprietary and name brands directly to consumers in an engaging and informative shopping experience via television, online and mobile. Evine reaches approximately 87 million cable and satellite television homes 24 hours a day with entertaining content in a comprehensive digital shopping experience. About Race to Erase MS Race to Erase MS is dedicated to the treatment and ultimate cure for MS.  Funding research is the core focus of the foundation and significant strides have been made to find the cause and cure of this debilitating disease.  At the event’s inception 24 years ago, the absence of medications and therapies encouraged its involvement; the Race has been instrumental in funding many pilot studies that have contributed to drugs now on the market and other very important therapies that are improving the lives of people suffering from MS. All funds raised support the Center Without Walls program, a unique collaboration of the world’s leading MS research scientists currently representing Harvard, Yale, Cedars Sinai, University of Southern California, Oregon Health Science University, UC San Francisco and Johns Hopkins.  This nationwide collaboration of physicians, scientists and clinicians are on the cutting-edge of innovative research and therapeutic approaches to treat MS.  It is the hope of the Race to Erase MS that in addition to combating MS through research in a clinical environment, awareness will be created by educating the public about this mysterious disease. Tickets to the 24th Annual Race to Erase MS Gala start at $1,000 and tables start at $10,000. To purchase tickets for the event, please contact info@erasems.org or (310) 440-4842.

Home > Press > Cedars-Sinai, UCLA Scientists Use New ‘Blood Biopsies’ With Experimental Device to Speed Cancer Diagnosis and Predict Disease Spread: Leading-Edge Research Is Part of National Cancer Moonshot Initiative Abstract: A team of investigators from Cedars-Sinai and UCLA is using a new blood-analysis technique and tiny experimental device to help physicians predict which cancers are likely to spread by identifying and characterizing tumor cells circulating through the blood. The investigators are conducting “liquid biopsies” by running blood through a postage-stamp-sized chip with nanowires 1,000 times thinner than a human hair and coated with antibodies, or proteins, that recognize circulating tumor cells. The device, the NanoVelcro Chip, works by “grabbing” circulating tumor cells, which break away from tumors and travel through the bloodstream, looking for places in the body to spread. Use of the chip in liquid biopsies could allow doctors to regularly and easily monitor cancer-related changes in patients, such as how well they’re responding to treatment. The research earned the lead investigators a place on the U.S. Cancer Moonshot program, an initiative led by former Vice President Joe Biden to make available more therapies to more patients and to prevent cancer. “It’s far better to draw a tube of blood once a month to monitor cancer than to make patients undergo repeated surgical procedures,” said Edwin Posadas, MD, medical director of the Urologic Oncology Program at Cedars-Sinai’s Samuel Oschin Comprehensive Cancer Institute and one of the lead investigators. “The power of this technology lies in its capacity to provide information that is equal to or even superior to traditional tumor sampling by invasive procedures.” Although some forms of prostate cancer are so slow-growing that they pose little risk to patients, other forms of the disease are lethal. Identifying which patients have which type of disease has become a crucial area of study because prostate cancer is one of the leading causes of cancer death among men in the U.S. Nearly 27,000 U.S. men are expected to die from the disease in 2017, according to the American Cancer Society. The research team has determined that in certain cancer cells, the nucleus is smaller than in other, more typical, cancer cells. Patients with the most advanced cases of aggressive prostate cancer have cells with these very small nuclei. The investigators’ teamwork also revealed that very small nuclei are associated with metastasis, or cancer spread, to the liver and lung in patients with advanced cases of prostate cancer. Those nuclei developed before the metastases were detected. Identifying very small nuclei early in the disease progression may help pinpoint which patients have high risk of developing cancer that can spread and be fatal. Hsian-Rong Tseng, PhD, professor, Department of Molecular and Medical Pharmacology in the David Geffen School of Medicine at UCLA and the other lead investigator, said that his work with Posadas is focused on improving the quality of life for cancer patients. “We’re on a mission to dramatically change patients’ everyday lives and their long-term outcomes,” Tseng said. “We now have powerful new tools to accomplish that.” Posadas and Tseng join an elite cadre of academicians, technology leaders and pharmaceutical experts as partners in the Blood Profiling Atlas in Cancer (BloodPAC) Project, a Moonshot program. Participants will collect and share data gathered from circulating tumor cells. Posadas and Tseng expect to contribute microscopic images from 1,000 circulating tumor cells that have not yet been analyzed, as well as additional data and cells they have cataloged. For the past five years, Posadas and Tseng have collected blood samples from cancer patients to profile and analyze the circulating tumor cells and other components. That process has helped them understand how prostate and other cancers evolve. The two investigators and their teams hope their findings will contribute to developing effective, targeted treatments for many types of cancer. “Minimally invasive methods to both diagnose and follow cancer, through simple blood tests, offer a unique and novel approach that can lead to earlier diagnosis and treatment, leading to more cures,” said Robert A. Figlin, MD, director of the Division of Hematology Oncology and deputy director of the Samuel Oschin Comprehensive Cancer Institute at Cedars- Sinai. About Cedars-Sinai Cedars-Sinai is a leader in providing high-quality healthcare encompassing primary care, specialized medicine and research. Since 1902, Cedars-Sinai has evolved to meet the needs of one of the most diverse regions in the nation, setting standards in quality and innovative patient care, research, teaching and community service. Today, Cedars-Sinai is known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai impacts the future of healthcare by developing new approaches to treatment and educating tomorrow’s health professionals. Additionally, Cedars-Sinai demonstrates a commitment to the community through programs that improve the health of its most vulnerable residents. About the David Geffen School of Medicine at UCLA Since opening in 1951, the David Geffen School of Medicine at UCLA has grown into an internationally recognized leader in research, medical education, patient care and public service. It has almost 2,000 full-time faculty members, including recipients of the Nobel Prize, the Pulitzer Prize and the National Medal of Science. More than 1,400 residents and fellows pursue advanced training at UCLA and its affiliated hospitals, which include Ronald Reagan UCLA Medical Center. For more information, please click If you have a comment, please us. Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Guise J.-M.,Oregon Health And Science University | O'Haire C.,Oregon Health And Science University | McPheeters M.,Vanderbilt University | Most C.,Oregon Health And Science University | And 4 more authors.
Journal of Clinical Epidemiology | Year: 2013

Objective: A major goal of patient-centered outcomes and comparative effectiveness research is to increase the involvement of stakeholders throughout the research process to provide relevant and immediately actionable information. In this report, we review the current practices for engaging stakeholders in prioritizing research. Study Design and Setting: To evaluate the range of approaches to stakeholder engagement, we reviewed the relevant literature and conducted semistructured interviews with (1) leading research organizations in the United States, Canada, and the United Kingdom; and (2) eight Evidence-based Practice Centers that engage stakeholders in comparative effectiveness research. Results: We identified 56 articles related to stakeholder engagement in research prioritization. Studies and research organizations interviewed frequently used mixed methods approaches combining in-person venues with structured ranking or voting processes such as Delphi. EPCs similarly used group web/conference calls combined with Delphi ranking or voting. Research organizations reported difficulties engaging the public and policy makers, and EPCs reported challenges engaging federal stakeholders. Conclusion: Explicit and consistent use of terminology about stakeholders was absent. In-person techniques were useful to generate ideas and clarify issues, and quantitative methods were important in the prioritization of research. Recommendations for effective stakeholder engagement and a reporting checklist were developed from the accumulation of findings. © 2013 Elsevier Inc. All rights reserved.

Kicielinski K.P.,University of Alabama at Birmingham | Chiocca E.A.,Brigham and Women's Hospital | Yu J.S.,Cedars Sinai | Gill G.M.,Oncolytics Biotech | And 2 more authors.
Molecular Therapy | Year: 2014

Reovirus, an oncolytic RNA virus exhibiting antiglioma activity, was shown in a previous single institution phase 1 study found that the inoculation of the virus to be well tolerated in patients with recurrent malignant glioma (MG). The goals of multicenter study reported herein were to determine the dose-limiting toxicity, maximum tolerated dose, and target lesion response rate when reovirus was administered in a novel fashion via intratumoral infusion for 72 hours in patients with recurrent malignant glioma. Fifteen adult patients were treated in a dose escalation study ranging from 1 × 10 8 to 1 × 10 10 tissue culture infectious dose 50, tentimes the dose achieved in the previous trial. Neurological, functional examinations, and imaging studies were completed pre-and postinfusion. There was one grade 3 adverse event (convulsions) felt to be possibly related to treatment, but no grade 4 adverse events considered probably or definitely related to treatment. Dose-limiting toxicity were not identified and a maximum tolerated dose was not reached. Evidence of antiglioma activity was seen in some patients. This first report of intratumoral infusion of reovirus in patients with recurrent malignant glioma demonstrated the approach to be safe and well tolerated, warranting further studies. © 2014 The American Society of Gene and Cell Therapy.

News Article | November 20, 2016
Site: marketersmedia.com

Beverly Hills Sinus Center is happy to announce the newest addition to their prestigious group, Dr. Evan Walgama! Dr. Walgama is a fellowship-trained sinus and skull base surgeon and will serve as Co-Director of the Beverly Hills Sinus Center in Cedars Sinai with Dr. Arthur Wu. He has trained under many nationally prominent sinus surgeons throughout his education and is proud to offer the highest level of care available to Los Angeles patients. Dr. Walgama specializes in chronic sinusitis, nasal polyposis, sinonasal tumors, and endoscopic skull base surgery. He enjoys treating the difficult-to-control sinusitis cases, particularly those patients who have required multiple previous sinus surgeries. His goal is to perform surgery that optimizes further medical management and keeps patients from having to return to surgery. He also treats complex skull disorders such as pituitary tumors, cerebrospinal fluid leaks, chordomas, and benign or malignant nose, sinus and nasopharynx tumors. These challenging cases are often handled in collaboration with other top tier physicians to ensure the best possible outcome. Dr. Walgama graduated with honors from the University of Texas at Austin with a Bachelors degree in philosophy. He received his M.D. from the University of Texas Southwestern Medical School in Dallas and was a junior member of Alpha Omega Alpha honor society. He completed a five-year residency in Otolaryngology at the same institution where he served as chief resident at Parkland Memorial Hospital. He then completed a one-year fellowship in Endoscopic Sinus and Skull Base Surgery at Stanford University under the mentorship of Peter Hwang, MD. In addition to his clinical practice, Dr. Walgama is active in clinical research. He has presented original research at national meetings and publishes in peer-reviewed journals. He is a member of the American Academy of Otolaryngology-Head and Neck Surgery and the American Rhinologic Society. The Beverly Hills Sinus Center is known as a center of excellence in Southern California for compassionate care and cutting edge research in the field of nasal and sinus diseases. Located in the world renown Cedars-Sinai Medical Center Towers and headed by Dr. Arthur Wu, the Beverly Hills Sinus Center is the premier sinus center serving the Greater Los Angeles Area. Click Here for additional information or contact Beverly Hills Sinus Center at (310) 423-1220. For more information, please visit http://www.beverlyhillssinus.com

Jackson W.C.,University of Michigan | Schipper M.J.,University of Michigan | Johnson S.B.,University of Michigan | Foster C.,University of Michigan | And 5 more authors.
European Urology | Year: 2016

Background Limited data exist to guide the use of androgen deprivation therapy (ADT) for men treated with radiation therapy (RT) after radical prostatectomy (RP). The optimal duration of ADT in this setting is unknown. Objective To determine if the duration of ADT influences clinical outcomes for men receiving post-RP RT. Design, setting, and participants A total of 680 men who received adjuvant radiation therapy (n = 105) or salvage radiation therapy (n = 575) between 1986 and 2010 at a single tertiary care institution were reviewed retrospectively. Median follow-up post-RT was 57.8 mo. Intervention RT was delivered using three-dimensional conformal or intensity-modulated RT in 1.8-Gy fractions. For patients treated with ADT, >80% were treated with a gonadotropin-releasing hormone agonist with or without a nonsteroidal antiandrogen. Outcome measurements and statistical analysis Biochemical failure (BF), distant metastasis (DM), prostate cancer-specific mortality (PCSM), and overall mortality were assessed using Kaplan-Meier analysis and propensity score analysis. Results and limitations Overall, 144 patients (21%) received ADT with post-RP RT, most of whom had high-risk disease features such as Gleason score 8-10, seminal vesicle invasion, or pre-RT prostate-specific antigen >1 ng/ml. Median ADT duration was 12 mo (interquartile range: 6.0-23.7). Patients who received <12 mo of ADT had an association with increased BF (hazard ratio [HR]: 2.27; p = 0.003) and DM (HR: 2.48; p = 0.03) compared with patients receiving ≥12 mo of ADT. The 5-yr rates of DM were 6.0% and 23% for ≥12 and <12 mo of ADT, respectively. On propensity score analysis controlling for pretreatment and treatment-related factors, each month of ADT was associated with a decreased risk for BF (HR: 0.95; p = 0.0004), DM (HR: 0.88; p = 0.0004), and PCSM (HR: 0.90; p = 0.037). These findings are limited by the retrospective nature of our analysis. Conclusions For men with high-risk disease features receiving ADT with post-RP RT, the duration of ADT is associated with clinical outcomes. Our findings suggest that for these men an extended course of ADT ≥12 mo may be preferable. Validation of our findings is needed. Patient summary We evaluated outcomes for men with high-risk disease features treated with androgen deprivation therapy (ADT) and radiotherapy after radical prostatectomy. Longer durations of ADT resulted in improved patient outcomes. © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Ryan R.W.J.,Cedars Sinai | Chowdhary A.,Duke University | Britz G.W.,Duke University
Surgical Neurology International | Year: 2012

Background: We sought to review the current literature with regards to future risks of hemorrhage following cerebral revascularization in Moyamoya disease (MMD). Methods: We performed a comprehensive literature review using PubMed to inspect the available data on the risk of hemorrhage after revascularization in MMD. Results: In this review, we identify the risk factors associated with hemorrhage in MMD both before and after cerebral revascularization. We included proposed pathophysiology of the hemorrhagic risk, role of the type of bypass performed, treatment options, and future needs for investigation. Conclusions: The published cases and series of MMD treatment do show a risk of hemorrhage after treatment with either direct or indirect bypass both in the immediate as well as long-term future. While there are no discernible patterns in the rate of these hemorrhages, there is Class III evidence for the predictive effect of multiple microbleeds on preoperative imaging. Also, whereas revascularization, both direct and indirect, has been shown to reduce ischemic complications from MMD, there is not an association with the risk of hemorrhage after the procedure. Further studies need to be performed to help evaluate what the risk factors are and how to counsel patients as to the long-term outlook of this disease process. Copyright © 2012 Britz GW.

Koopman S.G.,Cedars Sinai | Fuchs G.,Cedars Sinai
Journal of Endourology | Year: 2013

Purpose: To review our experience with retrograde intrarenal surgery (RIRS) for management of conditions associated with intrarenal stricture and present a treatment algorithm based on the series. Patients and Methods: RIRS was offered to all patients with symptomatic intrarenal stenosis regardless of location if stone burden was 2 cm or less. With a combined endourology and lithotripsy table, patients with stones between 2 and 3 cm were also offered RIRS using a combined approach of RIRS and shockwave lithotripsy (SWL). A total of 108 patients with symptomatic stones and caliceal diverticulum or infundibular stenosis were included in the data analysis. A standard technique was used in all cases. Failures or patients not suitable for RIRS were treated with either percutaneous nephrolithotomy (PCNL) or laparoscopic surgery. Results: Successful identification and dilation/incision of the stenotic opening was accomplished in 94% of cases. Seventy-five percent of stones were managed with basketing and/or holmium laser ablation. In these patients, 90% were stone free (<2 mm stone fragments). For stones between 2 and 3 cm, the use of holmium laser in combination with SWL provided stone-free rates of 75%. Five percent of patients needed PCNL because of larger stone burden and posterior location. Conclusions: With the appropriate equipment, RIRS provides a valid treatment option for patients with intrarenal strictures. While upper pole and midrenal lesions are ideal, lower pole segments may be approached as well. A treatment algorithm based on the results provides a simplified approach for the minimally invasive management of intrarenal stenosis. © Copyright 2013, Mary Ann Liebert, Inc.

Giuliano A.E.,Cedars Sinai | Gangi A.,Cedars Sinai
Breast Journal | Year: 2015

Sentinel lymph node biopsy (SLNB) is based on the hypothesis that the sentinel lymph node (SLN) reflects the lymph-node status and a negative SLN might allow complete axillary lymph node dissection (ALND) to be avoided. Past and current sentinel lymph node clinical trials for breast carcinoma have addressed the prognostic and therapeutic benefits of this technique and as such, SLNB has become a standard of care for select breast cancer patients. This article reviews the history of SLNB as well as current guidelines and recent controversies. © 2014 Wiley Periodicals, Inc.

Loading Cedars Sinai collaborators
Loading Cedars Sinai collaborators